This is the authors' abstract. We don't add key points for this paper.
Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer. (ClinicalTrials.gov number, NCT00089674.)
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: